The Johns Hopkins University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Credit Designation Statement
The Johns Hopkins University School of Medicine designates this enduring material for a maximum of 9.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Release Date: April 4, 2012
Expiration Date: April 4, 2015
Now in its seventh year, this two-day symposium has been planned for the providers of care to patients with rheumatic diseases. Given the wide variety of rheumatologic disorders, and an ever increasing number of diagnostic procedures and treatment options, it is necessary to provide clinicians with information about strategies for the early diagnosis of these conditions, novel state-of-the-art diagnostic tools, and opportunities to utilize the most effective treatments to ensure optimal patient outcomes.
This activity is intended for rheumatologists, internists, gerontologists, orthopedic surgeons, nurses, nurse practitioners, and other allied health professionals.
After attending this activity, the participant will demonstrate the ability to:
- Discuss immunology and its role in auto-immune diseases and new treatments
- Identify new diagnostic criteria for rheumatoid arthritis
- Discuss updated American College of Rheumatology and EULAR treatment guidelines for rheumatoid arthritis
- Discuss new and emerging issues in the management of osteoporosis
- Identify major issues related to the management of patients with lupus and anti-phospholipid syndrome
- Recognize which imaging sequences or views, (MRI, ultrasound, radiographs, etc.) reveal the most information when used in the diagnosis of rheumatic diseases
- Identify new information and treatments in the management of osteoarthritis
- Recognize new advances in elbow, hand and wrist conditions common in inflammatory arthritis
- Discuss new treatment strategies in Gout
- Discuss patient education and health literacy
- Identify new and emerging treatments through complimentary medicine for the rheumatic diseases
- Recognize available resources for people unable to access appropriate care
- Identify the importance of practice guidelines and their related protocols
- Identify and perform new treatment options for patients with psoriatic arthritis and ankylosing spondylitis
Notice About Off-Label Use Presentations
The Johns Hopkins University School of Medicine/ Sixth Annual Advances in the Diagnosis and Treatment of the Rheumatic Diseases (EM) may include presentations on drugs or devices, or use of drugs or devices, which have not been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice. The Johns Hopkins University School of Medicine is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations on off-label uses, does not imply an endorsement by Johns Hopkins of the uses, products, or techniques presented.
All rights reserved. No part of this syllabus may be used or reproduced in any manner whatsoever without written permission except in the case of brief quotations embodied in articles or reviews.
Instructions to obtain a CME Certificate for this activity
To obtain CME Credits for this activity, you must register online at http://www.hopkinscme.edu/CourseDetail.aspx/80029414 After you have registered and paid the $45 registration fee, please follow the steps given on the website to complete your post-test.
A Certificate of Credits will be given upon passing the post-test with a score of at least 70% or better. Registrations will not be accepted after April 4, 2015.
Policy on Speaker and Provider Disclosure
It is the policy of the Johns Hopkins University School of Medicine that the speaker and provider disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). The Johns Hopkins University School of Medicine OCME has established policies in place that will identify and resolve all conflicts of interest prior to this educational activity. Detailed disclosure will be made in the activity handout materials.
Full Disclosure Policy Affecting CME Activities
As a provider accredited by the Accreditation Council for Continuing Medical Education (ACCME), it is the policy of The Johns Hopkins University School of Medicine to require the disclosure of the existence of any relevant financial interest or any other relationship a faculty member or a provider has with the manufacturer(s) of any commercial product(s) discussed in an educational presentation. The presenting faculty reported the following:
|SPEAKERS NAME AND LECTURE TITLES||RELATIONSHIPS|
|John Carrino, MD, MPH : Musculoskeletal Radiology-Pearls for the Rheumatologist||Grants/Research: Carestream, Siemens and Toshiba; Consultant:Quality Medical Metrics|
|Maxime Dougados, MD : Incorporating the New Rheumatoid Arthritis Criteria and Guidelines into Practice||Consultant/Advisor/Grant: Abbott, Bristol-Myers Squibb, Pfizer, Roche and UCB|
|Janet Maynard, MD : Gone with the Gout: An Epic Tale of Crystal Induced Arthritis||Grants/Research: Takeda|
|Kenneth Saag, MD : Advances in Osteoporosis 2011: Opportunities and Challenges||Consultant: Amgen, Eli Lilly, Merck and Novartis; Grants/Research:Amgen, Eli Lilly, Merck and Novartis|
|Thomas Schnitzer, MD : Update on Pain Mechanisms of OA: Implications for Therapy||Grants/Research: Eli Lilly and Pfizer|
All other speakers have indicated that they have not received financial support for consultation, research or evaluation or have a financial interest relevant to their presentation.
Note: Grants to investigators at The Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
|Clifton Bingham, III, MD||
No other planners have indicated that they have any financial interests or relationships with a commercial entity.
Note: Grants to investigators at the Johns Hopkins University are negotiated and administered by the institution which receives the grants, typically through the Office of Research Administration. Individual investigators who participate in the sponsored project(s) are not directly compensated by the sponsor, but may receive salary or other support from the institution to support their effort on the project(s).
OFF-LABEL PRODUCT DISCUSSION
The following speakers have disclosed that their presentation will reference unlabeled/unapproved uses of drugs or products:
|NAME AND LECTURE TITLES||PRODUCT|
|Francesco Boin, MD : Management of Raynaud’s Diseases and Digital Ulcers in Scleroderma||Sildenafil, epoprostenol, botox|
|Case Discussion||Rituximab, cyclophosphamide and mofetil mycophenolate|
|Sonye Danoff, MD : Practical Pulmonology for the Rheumatologist||Prednisone, Azathioprine, Mycophenolate, Cyclophosphamide and LVLG|
|James Dunn, MD :Ophthalmology in Rheumatic Disease||Use of immunosuppressive drugs for uveitis and scleritis|
|Derek Fine, MD : Lupus Nephritis||All drugs used in the treatment of LN are off-label|
|Janet Maynard, MD : Gone with the Gout: An Epic Tale of Crystal Induced Arthritis||Kineret, Colchicine, Rilonacept and Canakinumab|
All other speakers have indicated that they will not reference unlabeled/unapproved uses of drugs or products.
- Finding Access to Care – Community, State and Federal Resources – Vickie Ensor-Bands, MSA, MSN, RN
Objective: To identify potential health care resources for low income, underserved and uninsured patients
- Management of Raynaud’s Disease and Digital Ulcers in Scleroderma – Francesco Boin, MD
Objective: To recognize and effectively manage the complications of Raynaud’s.
- Musculoskeletal Radiology – Pearls for the Rheumatologist – John Carrino, MD, MPH
Objective: To describe the merits and limitations of MRI, CT, US, radiography and molecular imaging for Rheumatology applications.
- Practical Pulmonology for the Rheumatologist – Sonye Danoff, MD, PhD
Objective: To describe the evaluation for pulmonary involvement in the patient with rheumatic disease.
- Incorporating the New Rheumatoid Arthritis Criteria and Guidelines into Practice – Maxime Dougados, MD
Objective: To describe the benefit for the patients of an early diagnosis and a treat to target approach.
- Ophthalmology in Rheumatic Disease – James Dunn, MD
Objective: To recognize differences in ocular manifestations of different rheumatologic diseases and their treatment.
- Lupus Nephritis – Derek Fine, MD
Objective: To describe the importance of proteinuria in the assessment of lupus nephritis
- Surgical Management of the Hand and Wrists – Scott Lifchez, MD, FACS
Objective: To identify hand and wrist problems caused by rheumatoid arthritis which can be improved with surgery
- Spondyloarthropathies- Is There Anything New Under the Sun? – Grant Louie, MD
Objective: To identify recent advances in the treatment of spondyloarthropathies
- Gone with the Gout: An Epic Tale of Crystal Induced Arthritis – Janet Maynard, MD
Objective: To describe recent advances in the diagnosis, management and imaging of gout
- Complementary Medicine and the Patient with Rheumatic Disease – Kristi Mizelle, MD
Objective: To recognize the appropriate usage of complementary medicine in the patient with rheumatic disease.
- Health Literacy and Patient Education-Are We Making the Grade? – Victoria Ruffing, RN, CCRP
Objective: To identify patient education meeting the Health Literacy Act requirement
- Advances in Osteoporosis 2011: Opportunities and Challenges – Kenneth Saag, MD
Objectives: To discuss new therapeutic options and clinical trial data in osteoporosis; To discuss safety concerns of osteoporosis therapy and recognize newer and improved osteoporosis care
- Update on Pain Mechanisms of Osteoarthritis: Implications for Therapy – Thomas Schnitzer, MD
Objective: To discuss the role of the nervous system in osteoarthritis pain.